broadsword
Brigadier
Huh? Infineon is a Chinese company? Since when?
I was not implying Infineon was a Chinese company. Just replying directly to Samu's statement.
Huh? Infineon is a Chinese company? Since when?
China developing fast reactors that will be cheaper than coal
, , , , , , , , ,
China will develop its own commercial scale fast reactor in 2023 with a more advanced version in 2030. They will then scale up production as part of a build up to around 400 gigawatts of nuclear power by 2050. This would be four times more than the nuclear power currently in the USA.
China will build a lot more hydro power, wind power and solar power but there are limitations based on running out of rivers to dam and how much solar and wind can be integrated into the electrical grid.
Conditions to Deploy Fast Reactors
• The scale of PWR is large enough which could provide initial fuel loading and refueling fuel to FR
• Uranium becomes expensive enough.
• Safety level has been validate and could be built at inland site.
• Cost is lower than coal power plant.
• China Nuclear Phase 1:
– Reprocessing plant of PWR spent fuel (provide Pu to FR).
– MOX fuel plant
– Breeding FR (BR≈1.2)
– Reprocessing plant of FR spent fuel
• China Nuclear Phase 2:
– Metal fuel plant
– Pyroprocessing plant
– High breeding FR with metal fuel (BR>1.2) while the nuclear grow fast, and
– Low breeding ratio (BR≈1) while nuclear energy maintain a fixed level.
I saw this on CCTV last week and it's pretty interesting work they did.Chinese scientists develop world's 1st oral HDAC inhibitor
Lu Xianping works in a lab at Shenzhen Chipscreen Biosciences Ltd. in Shenzhen, south China's Guangdong Province, May 20, 2015. Lu Xianping, together with other four returned overseas scientists, spent 14 years to develop Chidamide, the world's first oral HDAC inhibitor, which was given regulatory approval in January. (Xinhua/Mao Siqian)
HBI-8000 (chidamide) is a member of the benzamide class of histone deacetylase (HDAC) inhibitors designed to block the catalytic pocket of Class I HDACs. HBI-8000 is an orally bioavailable, low-nanomolar inhibitor of cancer-associated HDAC enzymes with favorable pharmacology and safety profiles. HBI-8000 inhibits cancer-associated Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10 at nanomolar concentrations and stimulates accumulation of acetylated histones H3 and H4 in tumor cells. Studies with human-derived tumor cell lines have demonstrated that HBI-8000 inhibits the growth of many tumor cell lines via multiple mechanisms of action, including epigenetic regulation of tumor cell growth and apoptosis, immunomodulatory effects such as activation of NK- and CD8 T-cell-mediated antitumor activity, as well as repression of genes associated with drug resistance. To date, HBI-8000 has been dosed globally in more than 280 patients with various types of hematological and solid tumors in several clinical trials, including a Phase 1 trial completed in the U.S.
The cost of chidamide for consumers is about 26,000 yuan a month, which is about 1/10 of what patients would pay in the US for some of the newest cancer medicines, but still unattainable for many low-income families in China.